Welcome to our dedicated page for Surface Oncology news (Ticker: SURF), a resource for investors and traders seeking the latest updates and insights on Surface Oncology stock.
Surface Oncology, Inc. (NASDAQ: SURF) is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies targeting the tumor microenvironment. This news hub provides investors and researchers with timely updates on SURF's therapeutic pipeline, strategic collaborations, and regulatory milestones.
Access comprehensive coverage of SURF's lead programs including SRF388 (anti-IL-27 antibody) and SRF114 (anti-CCR8 antibody), both designed to overcome immunosuppressive barriers in cancer treatment. Track developments from key partnerships with Novartis (CD73 program) and GlaxoSmithKline (PVRIG target), along with analysis of the proposed Coherus BioSciences merger.
Our curated news collection features verified updates on clinical trial progress, FDA designations, financial reports, and scientific presentations. Stay informed about SURF's innovative approach to achieving sustained anti-tumor responses through targeted immunotherapy mechanisms.
Bookmark this page for direct access to Surface Oncology's official press releases and objective analysis of their position in the competitive immuno-oncology landscape. Check regularly for updates on pipeline advancements and corporate developments shaping SURF's trajectory in cancer treatment innovation.
Surface Oncology (Nasdaq: SURF) announced that CEO Jeff Goater and CMO Robert Ross will participate in the H.C. Wainwright Global Healthcare Conference on September 14-15, 2020. They will discuss the company's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), along with their emerging pre-clinical pipeline, including SRF813 (targeting CD112R, aka PVRIG). Surface is focused on developing next-generation immunotherapies that target the tumor microenvironment, aiming to achieve sustained anti-tumor responses.
Surface Oncology (Nasdaq: SURF) announced a presentation at the Robert W. Baird Global Healthcare Conference on September 10, 2020. CEO Jeff Goater and CMO Robert Ross will discuss their lead immunotherapy programs, SRF617, targeting CD39, and SRF388, targeting IL-27, along with the preclinical pipeline, including SRF813, which targets CD112R (PVRIG).
The fireside chat is set for 1:25 pm EDT and will highlight Surface's innovative approach to cancer treatment via next-generation immunotherapies aimed at the tumor microenvironment.
Surface Oncology (Nasdaq: SURF) reported strong advancements in its clinical pipeline during Q2 2020, including the initiation of a Phase 1 trial for SRF388 and a collaboration with Merck to study SRF617 with KEYTRUDA. The company raised approximately $39 million through funding sources and maintained cash reserves of $112.5 million. R&D expenses decreased to $9.5 million, while G&A expenses dropped to $5.0 million, reflecting cost management efforts. The net loss for the quarter was $14.8 million, an improvement from $17.8 million in Q2 2019. Surface projects sufficient resources to operate into 2022.
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Jeff Goater will present at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:55 a.m. EDT. The presentation will cover Surface's lead programs, SRF617 targeting CD39, and SRF388 targeting IL-27, along with the emerging preclinical pipeline including SRF813 targeting CD112R (PVRIG). Live audio and archived webcasts will be available on the company's investor relations website.
Surface is focused on developing next-generation immunotherapies aimed at achieving sustained anti-tumor responses.
Surface Oncology (NASDAQ: SURF) has announced that its 2020 Annual Meeting of Stockholders will be held virtually due to ongoing COVID-19 concerns. The meeting is scheduled for June 10, 2020, at 11:00 a.m. EDT. Only stockholders who were on record as of April 15, 2020, can participate. Registration is required before June 8, 2020, to access the virtual meeting. All stockholders are encouraged to submit their votes in advance or vote online during the meeting. This decision prioritizes health and safety amidst the pandemic.
Surface Oncology (Nasdaq: SURF) has successfully raised approximately $28.9 million through its At-the-Market facility, selling around 10.9 million shares at $2.66 each. The capital will enhance Surface's balance sheet, supporting the clinical development of its key projects: SRF617 (targeting CD39), SRF388 (targeting IL-27), and SRF813 (targeting CD112R). This transaction exhausts the balance on the previous $30 million ATM facility, with JonesTrading acting as the sales agent.
Surface Oncology (Nasdaq: SURF) announced a clinical trial collaboration with Merck (NYSE: MRK) to evaluate the safety and efficacy of its investigational antibody therapy, SRF617, in combination with Merck's KEYTRUDA® in solid tumors, particularly gastric cancer. The Phase 1/1b study aims to address high unmet needs, specifically in patients resistant to checkpoint inhibition. Preclinical studies suggest SRF617 may enhance the immune response when paired with KEYTRUDA®. This collaboration aims to accelerate SRF617's clinical development, with positive implications for cancer treatment.
Surface Oncology (Nasdaq: SURF) announced updated preclinical data at the AACR 2020 Annual Meeting. The presentations focus on two lead antibody therapies: SRF617 (CD39 target) and SRF388 (IL-27 target), highlighting their effectiveness in enhancing chemotherapy and immunotherapy. Additional data on SRF813 (CD112R) and SRF231 (CD47) show significant preclinical anti-tumor activity and potential in combination treatments. Full posters will be available on Surface Oncology’s website following the event.
Surface Oncology (Nasdaq: SURF) announced that data from the Phase 1 study of SRF231, a high-affinity anti-CD47 antibody, will be presented at the ASCO 2020 Annual Meeting, occurring virtually from May 29-31. The presentation type is an e-poster with the abstract number 3064. The lead author is Amita Patnaik, and the session will focus on Developmental Therapeutics - Immunotherapy. Although the SRF231 clinical program was deprioritized in 2018, the Phase 1 study is now concluding. For full details, the poster will be available on Surface Oncology’s website after the presentation.
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Jeff Goater will present at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 10 a.m. EDT. The presentation will cover Surface's lead programs, SRF617 targeting CD39 and SRF388 targeting IL-27. Live audio and archived webcasts will be available on the company's investor relations website. Surface Oncology focuses on developing next-generation immunotherapies aimed at achieving sustained anti-tumor responses through innovative antibody therapies.
